
A meta-analysis of two Gynecologic Oncology Group (GOG) clinical trials shows a clear long-term survival benefit for intraperitoneal (IP) therapy over intravenous (IV) treatment of ovarian cancer. The results were presented at the 2013 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer in Los Angeles.